Article

Classification of vitreous detachment guides surgical procedure

The surgical approach chosen by Borja Corcóstegui, MD, to repair vitreous detachments is driven by the classification of the detachment. In addition, use of anti-vascular endothelial growth factor (VEGF) and small-gauge instruments can be useful in vitreous detachment repair, said Dr. Corcóstegui, of the University of Barcelona, Spain.

The surgical approach chosen by Borja Corcóstegui, MD, to repair vitreous detachments is driven by the classification of the detachment. In addition, use of anti-vascular endothelial growth factor (VEGF) and small-gauge instruments can be useful in vitreous detachment repair, said Dr. Corcóstegui, of the University of Barcelona, Spain.

The classification of the vitreous detachments that he uses ranges from Type 0 to Type 5:

  • Type 0, characterized by complete posterior vitreous detachment (PVD).
  • Type 1, characterized by one or more focal vitreoretinal attachments typically at the optic disc.
  • Type 2, characterized by broad vitreoretinal attachments, with attachments larger than 1 disc area in size and the presence or absence of underlying traction with an associated complication rate
  • Type 3, characterized by vitreous attachment at the disc along the arcades and over the macula with surgical complication rates up to 7%.
  • Type 4, characterized by vitreous attachment from the disc and major vascular arcades out to the extreme periphery, vitreous detached only over the macula and surgical complications up to 8% to 10%.
  • Type 5, characterized by the absence of PVD with surgical complication rates of from 12% to 15%.

Grades 0, 1, 2, and 3 can be addressed with small-gauge instruments (23- or 25-gauge) and grades 4 and 5 with 20-gauge instruments. When operating on the eyes of patients with grades 2 to 5 vitreous detachments, 0.05 ml of either bevacizumab (Avastin, Genentech) or ranicizumab (Lucentis, Genentech) is injected 2 to 7 days preoperatively to decrease the proliferation of new vessels and shrink the collagen tissue.

Dr. Corcóstegui said he prefers 23-gauge instrumentation because he can operate through a small port and there is higher efficacy when cutting membranes.

"Recognizing the degree of vitreoretinal attachment can be useful and can help estimate the complicate rate," he said. "Anti-VEGF drugs are helpful to the surgical technique as well as small-gauge instrumentation."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.